Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00319631|
Recruitment Status : Withdrawn (Under the discretion of the PI the study has been withdrawn.)
First Posted : April 27, 2006
Last Update Posted : January 30, 2017
|Condition or disease|
|Respiratory Distress Syndrome, Adult|
In previous lab experiments, we observed evidence of pulmonary edema following alveolar epithelial overexpression of VEGF, suggesting a potential role for VEGF in ARDS. In addition, we found that preventing VEGF from reaching its target receptor(s) by overexpressing a soluble form of a VEGF receptor protein prevents edema formation.
These observations heighten the plausibility of VEGF playing an important role in the development of increased pulmonary capillary permeability during acute lung injury. Understanding this role VEGF plays in ARDS consequently provides an ideal opportunity to discover new therapies for ARDS.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)|
|Actual Study Start Date :||January 2006|
|Primary Completion Date :||January 2017|
|Study Completion Date :||January 2017|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00319631
|United States, New York|
|Weill Medical College of Cornell University|
|New York City, New York, United States, 10021|
|Principal Investigator:||Robert J. Kaner, M.D.||Weill Medical College of Cornell University|